Related Experiment Video
Updated: May 4, 2026
Isolation and Expansion of Human Glioblastoma Multiforme Tumor Cells Using the Neurosphere Assay
Published on: October 30, 2011
Angiocentric glioma: a single center experience and literature review
Pengcheng Zuo1, Kai Jiang2, Wanjing Zou3
1Department of Neurosurgery, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China.
Objective:
Angiocentric glioma (AG) is a very rare neoplasm. Limited literature described this rare lesion and most of them are case reports. Here we report 21 patients with AG and review the literature.
Methods:
Clinical data from the 21 patients who underwent surgical treatment in our institute between 2015 and 2025 were reviewed. We also searched PubMed database between 2005 and 2025 using the keywords "angiocentric glioma" or "angiocentric gliomas" and 74 patients were reviewed.
Results:
The authors' cohort include 12 males and 9 females, with a mean age of 17.9 ± 17.9 years. Gross-total resection (GTR) and non-GTR were achieved in 15 and 6 patients, respectively. After a mean follow-up of 41.7 ± 31.4 months, no patient died and tumor recurrence occurred in 1 patient. In the literature between 2005 and 2025, 74 cases of AG were identified. Among them, 46 cases were males and 28 cases were females with a mean age of 14.7 ± 13.9 years. GTR, non-GTR and biopsy were achieved in 49, 17, 7 cases, respectively. After a mean follow-up of 29.4 ± 31.6 months, 2 patients died, for a mean follow-up of 32.7 ± 36.1 months, 5 patients suffered tumor recurrence. Among all cases that underwent immunohistochemical examination, 98.5% were positive for Glial Fibrillary Acidic Protein (GFAP) and 82.1% were positive for Epithelial Membrane Antigen (EMA). Genetic testing was performed in a total of 6 cases and all of them showed MYB-QKI gene fusion. Progression-Free Survival (PFS) rates at 1, 5, 10 years were 96%, 94% and 77% respectively, and Overall Survival (OS) rates at 1, 5, 10 years were 99%, 99% and 91%.
Conclusion:
AGs are rare tumors with a higher tendency in males and they usually involved the frontal and temporal lobe. In immunohistochemical studies, GFAP and EMA are frequently positive. The MYB-QKI gene fusion is a characteristic feature of this tumor. GTR was regarded as the best treatment. Although most AGs were clinically indolent, a few unusual cases showed aggressive behaviors. A larger cohort with long-term follow-up is necessary to verify our findings.
